Abstract 917: AZD2014, a dual mTORC1 and mTORC2 inhibitor is differentiated from allosteric inhibitors of mTORC1 in ER+ breast cancer
Sylvie M. Guichard(Novo Nordisk (United Kingdom)), Martin Pass(Amicus Therapeutics (United Kingdom)), Christine M. Chresta(AstraZeneca (United Kingdom)), James William Thomas Yates, Sarah V. Holt(Pharma Nord (United Kingdom)), Jon Curwen(AstraZeneca (United Kingdom)), Karine Malagu(Charles River Laboratories (Netherlands)), Sarah L. Pass(AstraZeneca (United Kingdom)), Marc Hummersone(Pharminox (United Kingdom)), Stephen Green(AstraZeneca (United Kingdom)), Mark J. Roth(National Cancer Institute), Gareth Hughes(AstraZeneca (United Kingdom)), Zoë Howard(United States Department of Defense), Barry R. Davies(Immodulon Therapeutics (United Kingdom)), Armelle Logié(Sorbonne Université), Dan Heathcote(AstraZeneca (United Kingdom))
Cited by 17
Related Papers
Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
|Molecular Cancer Therapeutics|2012|460
Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial‐to‐mesenchymal transition
|International Journal of Cancer|2013|350
Bub1 is required for kinetochore localization of BubR1, Cenp-E, Cenp-F and Mad2, and chromosome congression
|Journal of Cell Science|2004|344
Salmonella Enteritidis in shell eggs: Current issues and prospects for control
|Food Research International|2011|188